About Myosin-14
Myosin-14 (MYH14) is a protein
from Homo sapiens identified by UniProt accession
Q7Z406, 1995 residues long.
MolForge cross-references it against 0 known binders and
556 disease associations.
Target properties
| Protein name | Myosin-14 |
|---|
| UniProt accession | Q7Z406 |
|---|
| Gene | MYH14 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1995 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (556)
Diseases linked to this target (Open Targets).
- autosomal dominant nonsyndromic hearing loss 4A · score 0.73
- peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome · score 0.61
- deafness · score 0.52
- autosomal dominant nonsyndromic hearing loss · score 0.48
- neuroinflammatory disorder · score 0.34
- response to cisplatin · score 0.23
- platinum measurement · score 0.23
- head and neck squamous cell carcinoma · score 0.21
- genetic disorder · score 0.19
- lung adenocarcinoma · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q7Z406-F1 | alphafold | PREDICTED | 74.52 | — |
Amino-acid sequence (1995 residues)
MAAVTMSVPG RKAPPRPGPV PEAAQPFLFT PRGPSAGGGP GSGTSPQVEW TARRLVWVPS ELHGFEAAAL RDEGEEEAEV ELAESGRRLR LPRDQIQRMN PPKFSKAEDM AELTCLNEAS VLHNLRERYY SGLIYTYSGL FCVVINPYKQ LPIYTEAIVE MYRGKKRHEV PPHVYAVTEG AYRSMLQDRE DQSILCTGES GAGKTENTKK VIQYLAHVAS SPKGRKEPGV PGELERQLLQ ANPILEAFGN AKTVKNDNSS RFGKFIRINF DVAGYIVGAN IETYLLEKSR AIRQAKDECS FHIFYQLLGG AGEQLKADLL LEPCSHYRFL TNGPSSSPGQ ERELFQETLE SLRVLGFSHE EIISMLRMVS AVLQFGNIAL KRERNTDQAT MPDNTAAQKL CRLLGLGVTD FSRALLTPRI KVGRDYVQKA QTKEQADFAL EALAKATYER LFRWLVLRLN RALDRSPRQG ASFLGILDIA GFEIFQLNSF EQLCINYTNE KLQQLFNHTM FVLEQEEYQR EGIPWTFLDF GLDLQPCIDL IERPANPPGL LALLDEECWF PKATDKSFVE KVAQEQGGHP KFQRPRHLRD QADFSVLHYA GKVDYKANEW LMKNMDPLND NVAALLHQST DRLTAEIWKD VEGIVGLEQV SSLGDGPPGG RPRRGMFRTV GQLYKESLSR LMATLSNTNP SFVRCIVPNH EKRAGKLEPR LVLDQLRCNG VLEGIRICRQ GFPNRILFQE FRQRYEILTP NAIPKGFMDG KQACEKMIQA LELDPNLYRV GQSKIFFRAG VLAQLEEERD LKVTDIIVSF QAAARGYLAR RAFQKRQQQQ SALRVMQRNC AAYLKLRHWQ WWRLFTKVKP LLQVTRQDEV LQARAQELQK VQELQQQSAR EVGELQGRVA QLEEERARLA EQLRAEAELC AEAEETRGRL AARKQELELV VSELEARVGE EEECSRQMQT EKKRLQQHIQ ELEAHLEAEE GARQKLQLEK VTTEAKMKKF EEDLLLLEDQ NSKLSKERKL LEDRLAEFSS QAAEEEEKVK SLNKLRLKYE ATIADMEDRL RKEEKGRQEL EKLKRRLDGE SSELQEQMVE QQQRAEELRA QLGRKEEELQ AALARAEDEG GARAQLLKSL REAQAALAEA QEDLESERVA RTKAEKQRRD LGEELEALRG ELEDTLDSTN AQQELRSKRE QEVTELKKTL EEETRIHEAA VQELRQRHGQ ALGELAEQLE QARRGKGAWE KTRLALEAEV SELRAELSSL QTARQEGEQR RRRLELQLQE VQGRAGDGER ARAEAAEKLQ RAQAELENVS GALNEAESKT IRLSKELSST EAQLHDAQEL LQEETRAKLA LGSRVRAMEA EAAGLREQLE EEAAARERAG RELQTAQAQL SEWRRRQEEE AGALEAGEEA RRRAAREAEA LTQRLAEKTE TVDRLERGRR RLQQELDDAT MDLEQQRQLV STLEKKQRKF DQLLAEEKAA VLRAVEERER AEAEGREREA RALSLTRALE EEQEAREELE RQNRALRAEL EALLSSKDDV GKSVHELERA CRVAEQAAND LRAQVTELED ELTAAEDAKL RLEVTVQALK TQHERDLQGR DEAGEERRRQ LAKQLRDAEV ERDEERKQRT LAVAARKKLE GELEELKAQM ASAGQGKEEA VKQLRKMQAQ MKELWREVEE TRTSREEIFS QNRESEKRLK GLEAEVLRLQ EELAASDRAR RQAQQDRDEM ADEVANGNLS KAAILEEKRQ LEGRLGQLEE ELEEEQSNSE LLNDRYRKLL LQVESLTTEL SAERSFSAKA ESGRQQLERQ IQELRGRLGE EDAGARARHK MTIAALESKL AQAEEQLEQE TRERILSGKL VRRAEKRLKE VVLQVEEERR VADQLRDQLE KGNLRVKQLK RQLEEAEEEA SRAQAGRRRL QRELEDVTES AESMNREVTT LRNRLRRGPL TFTTRTVRQV FRLEEGVASD EEAEEAQPGS GPSPEPEGSP PAHPQ
Explore Myosin-14 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets